Regencell Bioscience Ltd - RGC Net Assets per Single Share

Public company logo of regencellbioscience.com (RGC)

The Regencell Bioscience (RGC) price chart on the GURU.Markets platform demonstrates the asset's volatility, which is influenced by trade wars and regulatory restrictions between China and the US. The current indicator stands at 0.03, while the company has no sales, is incurring losses, and requires constant financing. The business focuses on creating niche plant-based remedies to combat ADHD.

RGC: Regencell Corp Net Asset Value per Share 07/04/2022 - 10/26/2026

regencellbioscience.com - analytical breakdowns and key metrics (RGC)

- price and consensus price forecast:
Stock Price Regencell|RGC - Consensus Target
- market capitalization data:
Market Value Regencell Bioscience Holdings Limited|RGC - Business Value
- book capitalization data:
Book Value per Share Regencell Bioscience|RGC - Total Stockholders' Equity|Market Cap to Net Assets Ratio regencellbioscience.com|RGC - Company Total Assets
- debt and liquidity data:
Debt to Equity Regencell Bioscience|RGC - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Regencell Bioscience Holdings Limited|RGC - Company Cumulative Debt|Debt to Book Capitalization Ratio Regencell Bioscience Holdings Limited
Fundamental company valuation:RGC Regencell
Signature product of Regencell Bioscience Holdings Limited

Efficient outsourcing of development and production allows Regencell Bioscience (RGC) to optimize operating expenses. The price action of the book value per share reflects the accumulation of the issuer's net assets. This metric is calculated as the difference between all assets and liabilities, divided by the number of shares. It determines the real value of an investor's stake, excluding market speculation. The growing trend confirms the fundamental stability of the business.

Competitors of Regencell Bioscience (RGC)

BIIB: Book Value per Share|NBIX: Accounting Value per Share|Net Assets per Single Share Axsome Therapeutics|acadia-pharm.com (ACAD) - Equity per Share|Book Value per Share XENE (Xenon)|Net Asset Value per Share Viking Therapeutics Inc (VKTX)|Accounting Value per Share SUPN|Book Value per Share CPRX (Catalyst Corp)|Net Assets per Single Share Denali Therapeutics|harmonybiosciences.com - Accounting Value of a Share|BHVN (Biohaven) - Net Assets per Single Share|AMLX: Net Asset Value per Share|Net Assets per Single Share Trevi Pharma TRVI|Praxis Corp (PRAX) - Accounting Value of a Share|Book Value per Share AVXL (Anavex Life Sciences)|Net Asset Value per Share ceribell.com|PRTA: Book Value per Share|Book Value of One Share alector.com (ALEC)|ANNX: Book Value per Share|Omeros Corp - Net Asset Value per Share|Neurogene Inc. (NGNE) - Net Assets per Single Share|ACIU - Equity per Share|VYGR (Voyager Therapeutics, Inc.) - Book Value per Share|Neumora (NMRA) - Accounting Value per Share|Book Value per Share SCLX (Scilex Holding Co.)|Net Asset Value per Share TVGN|Net Assets per Single Share Alpha Cognition (ACOG)|Net Assets per Single Share CGTX (Cognition Therapeutics Inc.)|Net Assets per Single Share Inhibikase Therapeutics, Inc. IKT|SAVA - Net Assets per Single Share|Accounting Value per Share Assertio Therapeutics (ASRT)|COYA - Accounting Value of a Share|vistagen.com (VTGN) - Book Value per Share|Ovid Therapeutics (OVID) - Net Assets per Single Share|ABOS: Book Value per Share|Net Assets per Share CRVO|Alterity Therapeutics - Net Assets per Single Share|Net Asset Value per Share CLNN (clene.com)|Net Assets per Single Share PEPG|Net Assets per Share Jupiter Neurosciences, Inc. JUNS|RLMD: Book Value per Share|ANVS - Accounting Value per Share|gracetx.com - Book Value per Share|Firefly Neuro (AIFF) - Net Assets per Share|Book Value per Share KLTO (ANEW Medical)|Net Asset Value per Share NRSN|Net Assets per Single Share Reviva Pharmaceuticals Holdings, Inc. RVPH|Equity per Share metaviatx.com (MTVA)|NeurAxis, Inc - Book Value per Share|Accounting Value per Share Helius Medical Technologies, Inc. HSDT|PASG (Passage Bio Corp) - Book Value per Share|NEUP: Net Asset Value per Share|Net Assets per Single Share Minerva Neurosciences, Inc. NERV|Athira Pharma Inc (ATHA) - Accounting Value of a Share|Addex Therapeutics, Ltd. - Book Value per Share|Book Value of One Share Alzamend|Book Value per Share CYCN (Cyclerion Therapeutics)|Accounting Value per Share PTIX (protagenic.com)|KTTA - Net Assets per Single Share|Equity per Share Cortigent Inc CRGT|ATXI (Avenue Therapeutics, Inc) - Book Value per Share|BrainStorm Cell Therapeutics Inc. (BCLI) - Net Asset Value per Share|CARA: Accounting Value per Share|CHRO (chromocell.com) - Book Value per Share|ELYM - Net Assets per Single Share|Accounting Value of a Share ITCI|Longboard Pharma - Net Assets per Single Share|Net Asset Value per Share MRNS (Marinus Pharma)|Net Assets per Single Share NKGen Biotech, Inc.|Accounting Value of a Share neurobopharma.com NRBO|SAGE (Sage Therapeutics) - Book Value per Share|SNPX - Net Asset Value per Share|Book Value per Share TRVN (Trevena, Inc)|Vigil Neuroscience, Inc. (VIGL) - Book Value of One Share|Book Value per Share WENA (Anew Medical)|Net Asset Value per Share CERE